Innate Pharma S.A. (IPHA)

French immuno-oncology ADR with chronic losses, negative equity, and an explicit going-concern opinion in its April 2026 20-F — but the August 2026 Sobi lacutamab partnership ($75M upfront, up to $505M in milestones) plus a €30M equity raise have since rebuilt the cash runway and funded the confirmatory Phase 3. Trailing valuation metrics are non-meaningful on negative earnings, the discounted-cash-flow model implies downside versus the $2.16 price, and analyst targets near $6.67 reflect the post-Sobi optionality. A speculative, financing-dependent watchlist name — not yet an actionable entry.

Dominant near-term driver is the announced Sobi lacutamab license (2026-08-10; $75M upfront on closing subject to antitrust clearance, up to $505M milestones), carried as an unresolved bullish ongoing process and offset by the regulator-confirmed €30M dilutive capital increase (completed 2026-08-18, ~18.7% dilution) whose independent in-window coverage scored negative (FY2026 EPS cut, stock down 3.2%). Media delta determinate-flat (baseline ≈0.0 → scoring ≈+0.04, 11 aggregator items), Reddit in-window velocity indeterminate; moderate red-flag cap applied (dilutive offering; conflicting bullish/bearish signals), no severe flag.

Chart reads as a Sobi-catalyst uptrend holding above its key averages (price $2.16 vs SMA20 2.06, SMA50 1.91, SMA200 1.74, EMA21 2.09) with a strong ADX (42.24). Momentum is fading, though: RSI has cooled from 77 to 54.26, the MACD histogram is flat (0.00), and the stock prints a sequence of lower highs since the 2.71 spike (2.54, 2.30, 2.28). Volume has collapsed from the 08-10 catalyst surge (6.8M shares) to 20–59K shares/day. Mixed bullish/neutral → technicalScore 3. Tradability is separately blocked: fundamentalScore 2 (< 3 floor), avgDollarVolume20 ≈ $0.95M (< $5M floor), and recent 3-session average dollar volume ≈ $0.08M (< $1.5M recent-liquidity floor).